INTESTINAL ORGANOID IMMUNE-CONTROL INTEGRATED PLATFORM FOR THERAGNOSIS OF MICROBIOME AND IMMUNE CELL

It was identified that intestinal organoids derived human blood and endocytes of the present invention expressed the intestinal differentiation markers CGA, CDX2, LYZ, ECAD, KLF5, MUC2, Ki67, VIL, LGR5, SOX9, VIM, and SMA, thereby effectively reflecting intestinal conditions and can assay intestinal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: YANG, Seung Cheon, PARK, Jin Sil, JEONG, Ha Yeon, JHUN, Joo Yeon, CHOI, Jeong Won, LEE, Bo In, KIM, Seung Jun, LEE, Seung Yoon, CHO, Mi La, KIM, Ju Ryun, CHO, Keun Hyung, KIM, Ji Young, PARK, Sung Hwan, LEE, Han Hee, KIM, Sol, JU, Ji Hyeon
Format: Patent
Sprache:eng ; fre ; kor
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:It was identified that intestinal organoids derived human blood and endocytes of the present invention expressed the intestinal differentiation markers CGA, CDX2, LYZ, ECAD, KLF5, MUC2, Ki67, VIL, LGR5, SOX9, VIM, and SMA, thereby effectively reflecting intestinal conditions and can assay intestinal protection and intestinal secretions according to treatment with microbiomes. In addition, the (Bifidobacterium microbiome RAPO of the present invention was identified to upregulate the expression of IL-10 and REG3A and induce the expression of lysozyme, E-cadherin, and CGA and the proliferation of intestinal crypts in the intestinal organoids. Furthermore, intestinal organoids of the present invention were examined for responses to treatment with homologous PBMC to identify the reactivity of transplant rejection. In addition, an inflammatory bowel disease simulated avatar model of the present invention was identified to allow for effectively engrafting human blood immune cells thereto and induce the development of inflammatory bowel disease and the injury of intestinal tissues, thereby effectively reflecting diseased conditions of patients. Also, it was identified that injection of PBMC from patients with inflammatory bowel disease advanced the inflammatory bowel diseases, compared to injection of PBMC from normal persons and treatment with candidate materials could palliate the inflammatory bowel diseases, whereby therapeutic agents customized for patients can be screened. Il a été identifié que les organoïdes intestinaux dérivés du sang humain et les endocytes de la présente invention expriment les marqueurs de différenciation intestinale CGA, CDX2, LYZ, ECAD, KLF5, MUC2, Ki67, VIL, LGR5, SOX9, VIM et SMA, ce qui permet de prendre en compte efficacement les affections intestinales et de doser la protection intestinale et les sécrétions intestinales selon un traitement au moyen de microbiomes. De plus, le Bifidobacterium microbiome RAPO de la présente invention a été identifié pour réguler à la hausse l'expression de l'IL-10 et REG3A et induire l'expression du lysozyme, E-cadhérine, et CGA et la prolifération des cryptes intestinales dans les organoïdes intestinaux. De plus, les organoïdes intestinaux de la présente invention ont été examinés pour des réponses au traitement par des PBMC homologues pour identifier la réactivité du rejet de greffe. De plus, un modèle d'avatar simulé de maladie intestinale inflammatoire de la présente invention a été identifié p